Johnson & Johnson Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
Johnson & Johnson (JNJ) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of $0 for the 6-month period ending 2026-06-28, per its 10-Q filed 2026-07-23.
Financial Statements › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2026-07-23
- Johnson & Johnson fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2026-06-28 was $0.00.
- Johnson & Johnson fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2026-03-29 was $0.00.
- Johnson & Johnson fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2025-12-28 was $27.00M.
- Johnson & Johnson fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2025-09-28 was $50.00M, a 33.33% decline year-over-year.
- Johnson & Johnson fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2025 was $77.00M, a 2.67% increase from fiscal 2024.
- Johnson & Johnson fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2024 was $75.00M, a 31.58% increase from fiscal 2023.
- Johnson & Johnson fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2023 was $57.00M, a 418.18% increase from fiscal 2023.
- Johnson & Johnson fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2023 was $11.00M, a 77.08% decline from fiscal 2022.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-28 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $0.00 10-Q · filed 2026-07-23 | $27.00M derived: sum of 3 quarters · filed 2026-07-23 | $77.00M derived: sum of 4 quarters · filed 2026-07-23 | ||
| 2026-03-29 | $0.00 10-Q · filed 2026-04-22 | $27.00M derived: sum of 2 quarters · filed 2026-04-22 | $77.00M derived: sum of 3 quarters · filed 2026-04-22 | $77.00M derived: sum of 4 quarters · filed 2026-07-23 | ||
| 2025-12-28 | $27.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $77.00M derived: sum of 2 quarters · filed 2026-02-11 | $77.00M derived: sum of 3 quarters · filed 2026-07-23 | $77.00M 10-K · filed 2026-02-11 | ||
| 2025-09-28 | $50.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-22 | $50.00M derived: sum of 2 quarters · filed 2026-07-23 | $50.00M 10-Q · filed 2025-10-22 | $50.00M derived: sum of 4 quarters · filed 2026-07-23 | ||
| 2025-06-29 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $0.00 10-Q · filed 2026-07-23 | $0.00 derived: sum of 3 quarters · filed 2026-07-23 | $75.00M derived: sum of 4 quarters · filed 2026-07-23 | ||
| 2025-03-30 | $0.00 10-Q · filed 2026-04-22 | $0.00 derived: sum of 2 quarters · filed 2026-04-22 | $75.00M derived: sum of 3 quarters · filed 2026-04-22 | $75.00M derived: sum of 4 quarters · filed 2026-04-22 | ||
| 2024-12-29 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $75.00M derived: sum of 2 quarters · filed 2026-02-11 | $75.00M derived: sum of 3 quarters · filed 2026-02-11 | $75.00M 10-K · filed 2026-02-11 | ||
| 2024-09-29 | $75.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-22 | $75.00M derived: sum of 2 quarters · filed 2025-10-22 | $75.00M 10-Q · filed 2025-10-22 | $128.00M derived: sum of 4 quarters · filed 2026-02-11 | ||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-24 | $0.00 10-Q · filed 2025-07-24 | $53.00M derived: sum of 3 quarters · filed 2026-02-11 | $54.00M derived: sum of 4 quarters · filed 2026-02-11 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-04-23 | $53.00M derived: sum of 2 quarters · filed 2026-02-11 | $54.00M derived: sum of 3 quarters · filed 2026-02-11 | $56.00M derived: sum of 4 quarters · filed 2026-02-11 | ||
| 2023-12-31 | $53.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $54.00M derived: sum of 2 quarters · filed 2026-02-11 | $56.00M derived: sum of 3 quarters · filed 2026-02-11 | $57.00M 10-K · filed 2026-02-11 | ||
| 2023-10-01 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-23 | $3.00M derived: sum of 2 quarters · filed 2024-10-23 | $4.00M 10-Q · filed 2024-10-23 | $3.00M derived: sum of 4 quarters · filed 2025-02-13 | ||
| 2023-07-02 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-25 | $3.00M 10-Q · filed 2024-07-25 | $2.00M derived: sum of 3 quarters · filed 2025-02-13 | $14.00M derived: sum of 4 quarters · filed 2025-02-13 | ||
| 2023-04-02 | $1.00M 10-Q · filed 2024-05-01 | $0.00 derived: sum of 2 quarters · filed 2025-02-13 | $12.00M derived: sum of 3 quarters · filed 2025-02-13 | $12.00M derived: sum of 4 quarters · filed 2025-02-13 | ||
| 2023-01-01 | -$1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $11.00M derived: sum of 2 quarters · filed 2025-02-13 | $11.00M derived: sum of 3 quarters · filed 2025-02-13 | $11.00M 10-K · filed 2025-02-13 | ||
| 2022-10-02 | $12.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-27 | $12.00M derived: sum of 2 quarters · filed 2023-10-27 | $12.00M 10-Q · filed 2023-10-27 | $12.00M derived: sum of 4 quarters · filed 2024-02-16 | ||
| 2022-07-03 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31 | $0.00 10-Q · filed 2023-07-31 | $0.00 derived: sum of 3 quarters · filed 2024-02-16 | $0.00 derived: sum of 4 quarters · filed 2024-02-16 | ||
| 2022-04-03 | $0.00 10-Q · filed 2023-04-28 | $0.00 derived: sum of 2 quarters · filed 2024-02-16 | $0.00 derived: sum of 3 quarters · filed 2024-02-16 | $0.00 derived: sum of 4 quarters · filed 2024-02-16 | ||
| 2022-01-02 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | $0.00 derived: sum of 2 quarters · filed 2024-02-16 | $0.00 derived: sum of 3 quarters · filed 2024-02-16 | $48.00M 10-K · filed 2024-02-16 | ||
| 2021-10-03 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $0.00 derived: sum of 2 quarters · filed 2022-10-27 | $48.00M 10-Q · filed 2022-10-27 | $49.00M derived: sum of 4 quarters · filed 2023-02-16 | ||
| 2021-07-04 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-29 | $48.00M 10-Q · filed 2022-07-29 | $49.00M derived: sum of 3 quarters · filed 2023-02-16 | $60.00M derived: sum of 4 quarters · filed 2023-02-16 | ||
| 2021-04-04 | $48.00M 10-Q · filed 2022-04-29 | $49.00M derived: sum of 2 quarters · filed 2023-02-16 | $60.00M derived: sum of 3 quarters · filed 2023-02-16 | $87.00M derived: sum of 4 quarters · filed 2023-02-16 | ||
| 2021-01-03 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $12.00M derived: sum of 2 quarters · filed 2023-02-16 | $39.00M derived: sum of 3 quarters · filed 2023-02-16 | $99.00M 10-K · filed 2023-02-16 | -$99.00M 10-K · filed 2021-02-22 | |
| 2020-09-27 | $11.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-29 | $38.00M derived: sum of 2 quarters · filed 2021-10-29 | $98.00M 10-Q · filed 2021-10-29 | $168.00M derived: sum of 4 quarters · filed 2022-02-17 | ||
| 2020-06-28 | $27.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $87.00M 10-Q · filed 2021-07-29 | $157.00M derived: sum of 3 quarters · filed 2022-02-17 | $163.00M derived: sum of 4 quarters · filed 2022-02-17 | ||
| 2020-03-29 | $60.00M 10-Q · filed 2021-04-30 | $130.00M derived: sum of 2 quarters · filed 2022-02-17 | $136.00M derived: sum of 3 quarters · filed 2022-02-17 | $139.00M derived: sum of 4 quarters · filed 2022-02-17 | ||
| 2019-12-29 | $70.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $76.00M derived: sum of 2 quarters · filed 2022-02-17 | $79.00M derived: sum of 3 quarters · filed 2022-02-17 | $79.00M 10-K · filed 2022-02-17 | -$79.00M 10-K · filed 2020-02-18 | |
| 2019-09-29 | $6.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-23 | $9.00M derived: sum of 2 quarters · filed 2020-10-23 | $9.00M 10-Q · filed 2020-10-23 | $0.00 10-Q · filed 2019-10-28 | -$3.00M derived: sum of 4 quarters · filed 2021-02-22 | |
| 2019-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-24 | $3.00M 10-Q · filed 2020-07-24 | -$9.00M derived: sum of 3 quarters · filed 2021-02-22 | |||
| 2019-03-31 | $0.00 10-Q · filed 2020-04-29 | -$12.00M derived: sum of 2 quarters · filed 2021-02-22 | ||||
| 2018-12-30 | -$12.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-22 | -$172.00M 10-K · filed 2021-02-22 | ||||
| 2018-09-30 | -$160.00M 10-Q · filed 2019-10-28 | |||||
| 2017-12-31 | -$25.00M 10-K · filed 2020-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |